Standard BioTools to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2024 (GLOBE NEWSWIRE) — Standard BioTools Inc. (Nasdaq:LAB), today announced its President and Chief Executive Officer, Michael Egholm, PhD, will present at the upcoming Morgan Stanley 22nd Annual Global Healthcare Conference taking place Wednesday September 4th to Friday September 6th in New York City. Dr. Egholm’s fireside chat will be held Friday, September 6, 2024, at 8:30 a.m. ET.

The presentation will be webcast live and available on the Investor Relations page of the Company’s website at Events & Presentations. A recording of the webcast will be archived and available on the Standard BioTools Investor Relations page at investors.standardbio.com.

About Standard BioTools Inc.

Standard BioTools Inc. (Nasdaq:LAB), the parent company of SomaLogic Inc. and previously known as Fluidigm Corporation, has an established portfolio of essential, standardized next-generation technologies that help biomedical researchers develop medicines faster and better. As a leading solutions provider, the company provides reliable and repeatable insights in health and disease using its proprietary mass cytometry and microfluidics technologies, which help transform scientific discoveries into better patient outcomes. Standard BioTools works with leading academic, government, pharmaceutical, biotechnology, plant and animal research and clinical laboratories worldwide, focusing on the most pressing needs in translational and clinical research, including oncology, immunology and immunotherapy. Learn more at standardbio.com or connect with us on X, Facebook®, LinkedIn, and YouTube™.

For Research Use Only. Not for use in diagnostic procedures.

Limited Use Label License and other terms may apply: standardbio.com/legal/salesterms. Patent and License Information: standardbio.com/legal/notices.
Trademarks: standardbio.com/legal/trademarks. Any other trademarks are the sole property of their respective owners. ©2024 Standard BioTools Inc. (f.k.a. Fluidigm Corporation). All rights reserved.

Investor Contact: 

David Holmes
Gilmartin Group LLC
(332) 330-1031
ir@standardbio.com  

Staff

Recent Posts

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

WASHINGTON, Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P”…

55 mins ago

Capricor Therapeutics to Present at Upcoming Investor and Scientific Conferences

SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company…

55 mins ago

Safety Shot Announces Notice of Allowance for New Patent to Secure IP and Enforce Clinically Backed Claims

New Patent is Added to the Company’s Portfolio of Formulations that Rapidly Reduce Blood Alcohol…

55 mins ago

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

Results from this trial are expected in 2025SAN DIEGO, Sept. 06, 2024 (GLOBE NEWSWIRE) --…

55 mins ago

Amazfit T-Rex 3 Launches at IFA Berlin: Redefining Adventure for Modern Explorers

-Powered by Zepp Health, the T-Rex 3 Combines Durability with Advanced Privacy Features for Everyday…

4 hours ago